Mammalian milk osteopontin for enhancing immune responsiveness

Patent metadata

Field	Value
Publication number	US-2016136268-A1
Application number	US-201414903049-A
Country	US
Kind code	A1
Filing date	Jul 4, 2014
Priority date	Jul 5, 2013
Publication date	May 19, 2016
Grant date	—

Abstract

The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.

First claim

1 . Mammalian milk osteopontin for use as a medicament for enhancing immune resistance to an infectious disease in a mammal, wherein the osteopontin is for oral administration.

2 . Mammalian milk osteopontin for use according to claim 1 , wherein the mammalian milk is selected from among bovine, goat, sheep, camel, buffalo, dromedary, llama and any combination thereof.

3 . Mammalian milk osteopontin for use according to claim 1 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO: 1; and an active truncated osteopontin polypeptide of 40 kDa derived from the OPN polypeptide by in vivo peptide bond cleavage at a position that is C-terminal to the RGD motif.

4 . Mammalian milk osteopontin for use according to claim 1 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO: 1; and an active truncated osteopontin polypeptide wherein the amino acid sequence is residues 17-163 of SEQ ID NO: 1.

5 . Mammalian milk osteopontin for use according to claim 1 or 2 , wherein the osteopontin strengthens the humoral immunity in the mammal.

6 . Mammalian milk osteopontin for use according to any one of claims 1 to 5 , wherein the mammal is a human.

7 . Mammalian milk osteopontin for use according to any one of claims 1 to 6 , wherein the human belongs to an age group selected from among 0-5, 6-11, 12-18, 19-34, 35-44, 45-54, 55-64, 65-74, 75-84, and older than 84 years of age.

8 . Mammalian milk osteopontin for use according to any one of claims 1 to 7 , wherein the immune resistance to an infectious disease in a mammal is induced by vaccination.

9 . Mammalian milk osteopontin for use according to any one of claims 1 to 7 , wherein the infectious disease is selected from among influenza, diphtheria, tetanus, whooping cough, polio, measles, mumps and rubella, tuberculosis, hepatitis B, meningitis C, rotavirus, human papilloma virus, influenza type a, influenza type b, pneumococcal infection and shingles.

10 . A nutritional composition comprising the mammalian milk for use according to any one of claims 1 to 9 .

11 . A vaccine system comprising a vaccine and a mammalian milk osteopontin for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, wherein the osteopontin is for oral administration; wherein administration of the osteopontin enhances the immune resistance induced by the vaccine.

12 . The vaccine system for use according to claim 11 , wherein the mammalian milk osteopontin strengthens the humoral immunity in the mammal.

13 . The vaccine system for use according to claim 11 or 12 , wherein the osteopontin is selected from among bovine, goat, sheep, camel, buffalo, dromedary, llama, and any combination thereof.

14 . The vaccine system for use according to claim 11 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO: 1 and an active truncated osteopontin polypeptide of 40 kDa derived from the OPN polypeptide by in vivo peptide bond cleavage at a position that is C-terminal to the RGD motif.

15 . The vaccine system for use according to claim 11 , wherein the osteopontin is bovine and comprises an osteopontin polypeptide having an amino acid sequence of residues 17-278 of SEQ ID NO: 1; and an active truncated osteopontin polypeptide wherein the amino acid sequence is residues 17-163 of SEQ ID NO: 1.

16 . The vaccine system for use according to any one of claims 11 to 15 , wherein the osteopontin is for oral administration prior to; concurrently with; or subsequent to vaccination of the mammal, or a combination thereof.

17 . A vaccine system for use according to any one of claims 11 to 16 , wherein the mammal is a human.

18 . The vaccine system for use according to any one of claims 11 to 17 , wherein the infectious disease is selected from among influenza; diphtheria, tetanus, whooping cough, polio, measles, mumps and rubella, tuberculosis, hepatitis B, meningitis C; rotavirus, human papilloma virus; influenza type a, influenza type b, pneumococcal infection and shingles.

19 . The vaccine system for use according to any one of claims 11 to 18 , wherein the human belongs to an age group selected from among 0-5, 6-11, 12-18, 19-34, 35-44, 45-54, 55-64, 65-74, 75-84, and older than 84 years of age.

Assignees

• Arla Foods Amba

Inventors

• Kvistgaard Anne Staudt
• Wejse Peter Langborg
• Donovan Sharon
• Siegel Marcia H Monaco
• Comstock Sarah S

Classifications

• A61K2039/55

  characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K2039/575

  humoral response · CPC title

• A61K2039/542

  oral/gastrointestinal · CPC title

• A61K39/39 Primary

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title